Literature DB >> 23690555

Transmission of Onchocerca volvulus continues in Nyagak-Bondo focus of northwestern Uganda after 18 years of a single dose of annual treatment with ivermectin.

Moses N Katabarwa1, Tom Lakwo, Peace Habomugisha, Stella Agunyo, Edson Byamukama, David Oguttu, Ephraim Tukesiga, Dickson Unoba, Patrick Dramuke, Ambrose Onapa, Edridah M Tukahebwa, Dennis Lwamafa, Frank Walsh, Thomas R Unnasch.   

Abstract

The objective of the study was to determine whether annual ivermectin treatment in the Nyagak-Bondo onchocerciasis focus could safely be withdrawn. Baseline skin snip microfilariae (mf) and nodule prevalence data from six communities were compared with data collected in the 2011 follow-up in seven communities. Follow-up mf data in 607 adults and 145 children were compared with baseline (300 adults and 58 children). Flies collected in 2011 were dissected, and poolscreen analysis was applied to ascertain transmission. Nodule prevalence in adults dropped from 81.7% to 11.0% (P < 0.0001), and mf prevalence dropped from 97.0% to 23.2% (P < 0.0001). In children, mf prevalence decreased from 79.3% to 14.1% (P < 0.0001). Parous and infection rates of 401 flies that were dissected were 52.9% and 1.5%, respectively, whereas the infective rate on flies examination by polymerase chain reaction (PCR) was 1.92% and annual transmission potential was 26.9. Stopping ivermectin treatment may result in onchocerciasis recrudescence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23690555      PMCID: PMC3741251          DOI: 10.4269/ajtmh.13-0037

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  34 in total

1.  The Carter Center's assistance to river blindness control programs: establishing treatment objectives and goals for monitoring ivermectin delivery systems on two continents.

Authors:  F O Richards; E S Miri; M Katabarwa; A Eyamba; M Sauerbrey; G Zea-Flores; K Korve; W Mathai; M A Homeida; I Mueller; E Hilyer; D R Hopkins
Journal:  Am J Trop Med Hyg       Date:  2001-08       Impact factor: 2.345

2.  Onchocerciasis in the West Nile District of Uganda.

Authors:  G S NELSON
Journal:  Trans R Soc Trop Med Hyg       Date:  1958-07       Impact factor: 2.184

3.  Whither onchocerciasis control in Africa?

Authors:  D R Hopkins; F O Richards; M Katabarwa
Journal:  Am J Trop Med Hyg       Date:  2005-01       Impact factor: 2.345

4.  Onchocerciasis and its control. Report of a WHO Expert Committee on Onchocerciasis Control.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1995

5.  A simple technique to assess the total number of Onchocerca volvulus microfilariae in skin snips.

Authors:  H Schulz-Key
Journal:  Tropenmed Parasitol       Date:  1978-03

6.  Impact of mass treatment of onchocerciasis with ivermectin on the transmission of infection.

Authors:  H R Taylor; M Pacqué; B Muñoz; B M Greene
Journal:  Science       Date:  1990-10-05       Impact factor: 47.728

7.  Onchocerca volvulus: comparison of field collection methods for the preservation of parasite and vector samples for PCR analysis.

Authors:  L Toé; C Back; A G Adjami; J M Tang; T R Unnasch
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

8.  Feasibility of measuring compliance to annual ivermectin treatment in the African Programme for Onchocerciasis Control.

Authors:  William R Brieger; Joseph C Okeibunor; Adenike O Abiose; Richard Ndyomugyenyi; William Kisoka; Samuel Wanji; Elizabeth Elhassan; Uche V Amazigo
Journal:  Trop Med Int Health       Date:  2007-02       Impact factor: 2.622

9.  After a decade of annual dose mass ivermectin treatment in Cameroon and Uganda, onchocerciasis transmission continues.

Authors:  Moses Katabarwa; Albert Eyamba; Peace Habomugisha; Tom Lakwo; Same Ekobo; Joseph Kamgno; Thomas Kuete; Richard Ndyomugyenyi; Ambrose Onapa; Mkpouwoueiko Salifou; Marcelline Ntep; Frank O Richards
Journal:  Trop Med Int Health       Date:  2008-07-08       Impact factor: 2.622

Review 10.  The achievements and challenges of the African Programme for Onchocerciasis Control (APOC).

Authors:  A Sékétéli; G Adeoye; A Eyamba; E Nnoruka; P Drameh; U V Amazigo; M Noma; F Agboton; Y Aholou; O O Kale; K Y Dadzie
Journal:  Ann Trop Med Parasitol       Date:  2002-03
View more
  13 in total

1.  Efficacy of three-week oxytetracycline or rifampin monotherapy compared with a combination regimen against the filarial nematode Onchocerca ochengi.

Authors:  Germanus S Bah; Emma L Ward; Abhishek Srivastava; Alexander J Trees; Vincent N Tanya; Benjamin L Makepeace
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

2.  Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis.

Authors:  Wilma A Stolk; Martin Walker; Luc E Coffeng; María-Gloria Basáñez; Sake J de Vlas
Journal:  Parasit Vectors       Date:  2015-10-22       Impact factor: 3.876

3.  Factors Associated with Ivermectin Non-Compliance and Its Potential Role in Sustaining Onchocerca volvulus Transmission in the West Region of Cameroon.

Authors:  Laura Senyonjo; Joseph Oye; Didier Bakajika; Benjamin Biholong; Afework Tekle; Daniel Boakye; Elena Schmidt; Elizabeth Elhassan
Journal:  PLoS Negl Trop Dis       Date:  2016-08-16

4.  Nodding syndrome (NS) and Onchocerca Volvulus (OV) in Northern Uganda.

Authors:  David Kitara Lagoro; Denis Anywar Arony
Journal:  Pan Afr Med J       Date:  2017-09-04

5.  Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal.

Authors:  Martin Walker; Wilma A Stolk; Matthew A Dixon; Christian Bottomley; Lamine Diawara; Mamadou O Traoré; Sake J de Vlas; María-Gloria Basáñez
Journal:  Epidemics       Date:  2017-03       Impact factor: 4.396

6.  Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections.

Authors:  Hugo C Turner; Martin Walker; Thomas S Churcher; María-Gloria Basáñez
Journal:  Parasit Vectors       Date:  2014-05-26       Impact factor: 3.876

7.  Quantitative analyses and modelling to support achievement of the 2020 goals for nine neglected tropical diseases.

Authors:  T Déirdre Hollingsworth; Emily R Adams; Roy M Anderson; Katherine Atkins; Sarah Bartsch; María-Gloria Basáñez; Matthew Behrend; David J Blok; Lloyd A C Chapman; Luc Coffeng; Orin Courtenay; Ron E Crump; Sake J de Vlas; Andy Dobson; Louise Dyson; Hajnal Farkas; Alison P Galvani; Manoj Gambhir; David Gurarie; Michael A Irvine; Sarah Jervis; Matt J Keeling; Louise Kelly-Hope; Charles King; Bruce Y Lee; Epke A Le Rutte; Thomas M Lietman; Martial Ndeffo-Mbah; Graham F Medley; Edwin Michael; Abhishek Pandey; Jennifer K Peterson; Amy Pinsent; Travis C Porco; Jan Hendrik Richardus; Lisa Reimer; Kat S Rock; Brajendra K Singh; Wilma Stolk; Subramanian Swaminathan; Steve J Torr; Jeffrey Townsend; James Truscott; Martin Walker; Alexandra Zoueva
Journal:  Parasit Vectors       Date:  2015-12-09       Impact factor: 3.876

8.  Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.

Authors:  Jorge Cano; Maria-Gloria Basáñez; Simon J O'Hanlon; Afework H Tekle; Samuel Wanji; Honorat G Zouré; Maria P Rebollo; Rachel L Pullan
Journal:  Parasit Vectors       Date:  2018-01-31       Impact factor: 3.876

9.  Macrofilaricidal Efficacy of Repeated Doses of Ivermectin for the Treatment of River Blindness.

Authors:  Martin Walker; Sébastien D S Pion; Hanwei Fang; Jacques Gardon; Joseph Kamgno; Maria-Gloria Basáñez; Michel Boussinesq
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

10.  Community-directed vector control to supplement mass drug distribution for onchocerciasis elimination in the Madi mid-North focus of Northern Uganda.

Authors:  Benjamin G Jacob; Denis Loum; Thomson L Lakwo; Charles R Katholi; Peace Habomugisha; Edson Byamukama; Edridah Tukahebwa; Eddie W Cupp; Thomas R Unnasch
Journal:  PLoS Negl Trop Dis       Date:  2018-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.